Posted by Michael Wonder on 28 Jan 2023
Bristol Myers Squibb receives positive CHMP opinion for Reblozyl (luspatercept) for adult patients with anaemia-associated, non-transfusion-dependent beta thalassaemia
27 January 2023 - In the pivotal BEYOND study, Reblozyl significantly increased haemoglobin levels, which were sustained over longer time compared to placebo
Bristol Myers Squibb today announced the CHMP of the EMA has recommended approval of Reblozyl (luspatercept) as a treatment for adult patients with anaemia associated with non‑transfusion-dependent beta thalassaemia.
